Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent. This is a 31 percent increase over losses of $(1.00) per share from
Tvardi lost less money than Wall Street expected this quarter, and they're losing less money than they did a year ago. When a company is improving its losses over time, it's a sign things might be heading in a better direction.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.